Medical/Pharmaceuticals
BD to become exclusive global license partner (excluding China) for Bactiguard coated Foley catheters
STOCKHOLM, Dec. 14, 2023 /PRNewswire/ -- Bactiguard Holding AB (publ.) today announces strengthened ties with leading global medical technology company Becton Dickinson & Company (BD), Bactiguard's longest and strongest license collaboration. An interim agreement has been signed granting BD an exc...
2023-12-14 17:53
1388
Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs
SHANGHAI, Dec. 14, 2023 /PRNewswire/ -- The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced today that it will invest approximatelyUS$3.3 million (approximately 500 million yen[1]) in a global multicenter Phase III clinical trial project (the "Program") led by Fosun Ph...
2023-12-14 17:00
3508
Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China's National Reimbursement Drug List
SHANGHAI and HONG KONG, Dec. 14, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cance...
2023-12-14 09:55
1641
The Inaugural Fosun Health Conference on Guangdong-Hong Kong-Macao Healthcare Development Integration Held in Hong Kong to Promote "Three Links" Development
HONG KONG, Dec. 14, 2023 /PRNewswire/ -- The Inaugural Fosun Health Conference onGuangdong-Hong Kong-Macao Healthcare Development Integration was successfully held inHong Kong by Fosun Health on December 12, 2023. With the background of integrating medical services ofGuangdong, Hong Kong and Maca...
2023-12-14 09:00
3491
Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib (ABSK021)
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics") today announced that its CSF-1R inhibitor pimicotinib (ABSK021) has been granted the fast track designation ("FTD") by the U.S. FDA for the treatment of tenosynovial giant cell tumor ("TGCT") patients ...
2023-12-14 08:30
1339
Crown Aesthetics Announces Groundbreaking Study on Skin Microbiome-Optimized BIOJUVE™ Regimen
Study Reveals Remarkable Results in Aesthetic Treatment Recovery DALLAS, Dec. 14, 2023 /PRNewswire/ -- Crown Aesthetics, a Crown Laboratories, Inc. company ("Crown"), announced today that its groundbreaking clinical study, recently accepted for publication in the Journal of Clinical and Aesthetic...
2023-12-14 03:56
1368
Immunocan Provides Update on Business Operations, Highlighting Launch of New Gene-edited Mice Generating Fully Human Heavy-chain-only Antibodies and Advances in Partner Pipeline
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Shanghai Immunocan Biotech Co., Ltd. ("Immunocan") announcesthe launch of its ImmuMab Heavy® mice. These gene-edited mice, developed by modifying the constant region genes of heavy chains in the ImmuMab® mouse, generate fully human heavy-chain-only antibodi...
2023-12-13 22:00
1522
WAT Medical Joins World's Largest Boat Show
VANCOUVER, BC, Dec. 13, 2023 /PRNewswire/ -- Discover Boating Miami International Boat Show (DBMIBS) is the world's largest boat and yacht show. The convention, which attracts over 100,000 visitors from more than 35 countries, provides an opportunity for aquatic innovations and consumer products...
2023-12-13 22:00
1271
Virtual twin to improve treatment with cancer immunotherapies
COLOGNE, Germany, Dec. 13, 2023 /PRNewswire/ -- An international team started the research project CERTAINTY inDecember 2023. Together with partners from science, industry and the healthcare sector, the project team led by the Fraunhofer Institute for Cell Therapy and Immunology IZI aims to devel...
2023-12-13 21:06
1164
Molecular Loop Biosciences Receives $1.8 Million to Expand Multi-pathogen Genomics Products for Respiratory Infections
WOBURN, Mass., Dec. 13, 2023 /PRNewswire/ -- Molecular Loop Biosciences, Inc., an innovator at the forefront of targeted sequencing technologies, is pleased to announce that it has received a$1.8 million grant from the Bill & Melinda Gates Foundation to further its groundbreaking work in the fiel...
2023-12-13 21:00
1401
Alebund Reports Update for AP306 (EOS789), a First-in-Class Pan-inhibitor of Sodium-dependent Phosphate Transporters, from a Completed Phase II Clinical Trial in Patients with Hyperphosphatemia on Hemodialysis
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Alebund Pharmaceuticals
2023-12-13 21:00
1434
Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent
MELBOURNE, Australia and SAN DIEGO, Dec. 13, 2023 /PRNewswire/ -- Imagion Biosystems Limited (ASX: IBX) recently announced positive results following completion of the IBI10103 phase I clinical trial evaluating the safety and clinical feasibility ofMagSense® HER2 Imaging Agent (MSH2IA) as an adju...
2023-12-13 19:00
1669
Transcenta Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging
PRINCETON, N.J. and SUZHOU, China, Dec. 13, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces ...
2023-12-13 18:01
1861
Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Dizal today announced that the results of a phase 2 pivotal study of sunvozertinib for the treatment of platinum-pretreated non-small-cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations (exon20ins) (WU-KONG6) were published in the peer-...
2023-12-13 18:00
1280
Live from ASH 2023 | Results from Chinese Studies of Olverembatinib Presented in Oral Report at the ASH Annual Meeting for the Sixth Consecutive Year, Including Data Showing Promising Efficacy in Patients with TKI-Resistant and/or Intolerant CML-CP
SUZHOU, China and ROCKVILLE, Md., Dec. 13, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a randomized...
2023-12-13 16:47
2160
Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT® 's Seventh Indication and BYVASDA®'s Eighth Indication
ROCKVILLE, Md. and SUZHOU, China, Dec. 13, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2023-12-13 12:56
2672
WuXi Vaccines Wins Second Consecutive "Best Vaccine CMO Award" at AVEA 2023
SINGAPORE, Dec. 12, 2023 /PRNewswire/ -- WuXi Vaccines, a leading global vaccine Contract Development and Manufacturing Organization (CDMO), was named "Best Vaccine CMO of the Year" for the second consecutive year at the 2023 Asia-Pacific Vaccine Excellence Awards (AVEA) ceremony. The AVEA 202...
2023-12-13 08:30
1256
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate
--First Chinese RSV PreF Vaccine Candidate to Enter Clinical Trial Stage--
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
2023-12-13 07:42
1382
CARsgen Presents Updated Research Results on Zevor-cel at 2023 ASH Annual Meeting
SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2023 American Society of Hematology ("ASH") Annual Meetin...
2023-12-12 21:50
1319
The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA
SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the NDA for new indication of HANSIZHUANG, serplulimab, an innovative anti-PD-1 mAb independently developed by the company, in combination with chemotherapy as a first-line treatment for patients with...
2023-12-12 20:30
1749
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 276 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 274 media titles]
2024-04-24 17:09
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
7859
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
2024-04-24 17:09
6954
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
2024-04-23 15:43
5072